Use of bufadienolides compound and bufadienolides salinization compound in preparing medicine for treating gynecological tumor

The technology of a salt and a medicine is applied to the application field of bufastenoid compounds and bufastene salts in the preparation of medicines for treating gynecological tumors, which can solve the problems of high incidence of adverse reactions, complex components of toad preparations and the like, and achieve convenient Clinical application, strong anti-cancer effect, clear effect of main components

Inactive Publication Date: 2011-05-04
NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The technical problem to be solved by the present invention is to overcome the defects of complex components of toad preparations and high incidence of adverse reactions, and to provide a kind of bufa steroid compound and bufa steroid salt as active ingredients to prepare and treat gynecological diseases with clear ingredients and controllable quality. Application of drugs for tumor diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of bufadienolides compound and bufadienolides salinization compound in preparing medicine for treating gynecological tumor
  • Use of bufadienolides compound and bufadienolides salinization compound in preparing medicine for treating gynecological tumor
  • Use of bufadienolides compound and bufadienolides salinization compound in preparing medicine for treating gynecological tumor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1: Inhibitory effect of bufasterene extract, cinobufagin, bufafelin, bufafetal or jenobufafeline on human ovarian cancer cells:

[0026] According to the method of MTT experiment, the inhibitory effect of bufadene extract, cinobufafelin, bufafelin, bufafetalin or bufafetalin on human ovarian cancer cells (A2780) was investigated.

[0027]Experimental results: The experimental results showed that bufasterene extracts, cinobufagin, bufalin, bufafetalin or bufafetalin all had a strong inhibitory effect on human ovarian cancer cell A2780, and each dose group showed A better dose-effect relationship was obtained. The specific experimental results are shown in Table 1 and Table 2.

[0028] Table 1 The effect of bufalin extract on human ovarian cancer cells (A2780)

[0029]

[0030] Table 2 Effects of cinobufagin, bufafolin, bufafetolin and jenobubafalin on human ovarian cancer cell A2780

[0031]

Embodiment 2

[0032] Example 2: Inhibitory effect of bufasterene extract, cinobufagin, bufafelin, bufafetal or jenobufafeline on human ovarian cancer cells (SK-OV-3).

[0033] The inhibitory effects of bufadene extract, cinobufafeline, bufafelin, bufafetalin or bufafetalin on human ovarian cancer cells (SK-OV-3) were investigated according to the method of MTT experiment.

[0034] The experimental results showed that bufasterene extracts, cinobufagin, bufalin, bufafetalin or bufafetalin all had strong inhibitory effects on human ovarian cancer cells (SK-OV-3). The group showed a good dose-effect relationship. The specific experimental results are shown in Table 3 and Table 4.

[0035] Table 3 The effect of bufasterene extract on human ovarian cancer cells (SK-OV-3)

[0036]

[0037] Table 4 Effects of cinobufagin, bufafolin, bufafetoxin and jenobufafetoxin on human ovarian cancer cells (SK-OV-3)

[0038]

Embodiment 3

[0039] Example 3: Inhibitory effect of bufasterene extract, cinobufagin, bufafelin, bufafetal or jenobufafeline on human cervical cancer cells (SiHa).

[0040] The inhibitory effect of bufadene extract, cinobufalin, bufafelin, bufafetalin or bufafetalin on human cervical cancer cells (SiHa) was investigated according to the method of MTT experiment.

[0041] The experimental results showed that the bufasterene extract, cinobufagin, bufalin, bufafetalin or bufafetalin all had a strong inhibitory effect on human cervical cancer cells (SiHa). Good dose-response relationship. The specific experimental results are shown in Table 5 and Table 6.

[0042] The effect result of table 5 bufasterene extract on human cervical cancer cells (SiHa)

[0043]

[0044] Table 6 Effects of cinobufagin, bufafalin, bufafetolin and jenobubafafeline on human cervical cancer cells (SiHa)

[0045]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of a bufadienolide compound and a bufadienolide salt compound in preparing a medicine for treating gynecological tumor. Anti-cancer experiments of four gynecological tumor, namely human ovarian cancer cells (A2780), human ovarian cancer cells (SK-OV-3), human cervical carcinoma cells (SiHa) and human endometrial cancer cells (shikawa) are carried out in vitro through a bufadienolide extract and monomeric compounds, namely cinobufagin, bufalin, bufotalin and gamabufotalin as well as hydrochlorides or sulfates of the four monomeric compounds, and an experimental result shows that the bufadienolide extract, the monomeric compounds, namely the cinobufagin, the bufalin, the bufotalin and the gamabufotalin, and the hydrochlorides or the sulfates of the four monomeric compounds have strong inhibition effect on four gynecological tumor cells. The anti-cancer activity of the bufadienolide compound and the bufadienolide salt compound is stronger than that of apositive drug paclitaxel, and the bufadienolide compound and a bufadienolide salt compound have small adverse reaction and expect to be developed into a novel anti-cancer drug.

Description

technical field [0001] The invention relates to the new application of bufasterene compounds and bufasterene salts, in particular to the application of bufasterene compounds and bufasterene salts in the preparation of medicines for treating gynecological tumor diseases. Background technique [0002] Gynecological tumors are major diseases that endanger women's health. Common malignant tumors include endometrial cancer, cervical cancer, breast cancer, ovarian cancer, etc. The prevalence and mortality of cervical cancer in my country account for about one-third of the world. one. Treatment of gynecological tumors The treatment options routinely adopted by domestic and foreign medical circles are chemotherapy, radiation therapy and surgical resection. While achieving certain clinical curative effect, this program also brought patients serious medical problems due to the toxic and side effects of chemical drugs, radiation damage caused by radiotherapy, and iatrogenic problems an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/585C07J19/00A61P35/00A61P15/00
Inventor 马宏跃段金廒周婧唐于平
Owner NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap